US regulatory status: approved.
biotech · Hypertension · Essential Hypertension · QNTM
Quantum Pharmaceuticals
Quantum Biopharma
Quantum Pharmaceuticals drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
volkova 6A-1206, Moscow, 141700, RU, CA HQ
2004 Founded
29 Employees
Public company Type
QNTM · NYSE Ticker
Company details
- Status
- Public
- HQ
- volkova 6A-1206, Moscow, 141700, RU, CA
- Founded
- 2004
- Employees
- 29
- Programs
- 18
- Drugs
- 17
- Patents
- 36
Quantum Pharmaceuticals pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Quantum Pharmaceuticals drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Quantum Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Quantum Pharmaceuticals's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Quantum Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor antagonist
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to Quantum Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 2A.
- Target
- 5-hydroxytryptamine receptor 2A
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to Quantum Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Quantum Pharmaceuticals in public FDA and regional records.